20 DECEMBER 2024
ANANDA PHARMA PLC (formerly ANANDA DEVELOPMENTS PLC)
("Ananda" or the "Company")
Change of Name
Ananda (AQSE: ANA), a Company focused on the development of cannabinoid therapies for the treatment of a range of complex conditions, is pleased to announce that it has changed its name to ANANDA PHARMA plc.
Melissa Sturgess, CEO, commented: "This name change confirms our drive to bring licensed cannabinoid medicines to patients. We believe the best way to support patients in need and to deliver strong returns to our shareholders is via our continued commitment to the biopharmaceutical drug development pathway. The new name, Ananda Pharma, reflects this ambition.'
The new name will be reflected on AQUIS at 8.00 a.m. on 23 December 2024. The Company's ticker will stay the same : 'ANA' and the Company's ISIN (GB00BDQPXQ60) and SEDOL (BDQPXQ6) will also remain unchanged. In order to reflect its new name, the Company's website address has been changed to www.anandapharma.co.uk. A first look at the Company's new logo and branding is available at the bottom of this RNS.
Shareholder documents of title will be unaffected by the change of name and existing share certificates should be retained and remain valid. Any new share certificates to be issued will bear the new name, ANANDA PHARMA plc.
-Ends-
The Directors of the Company accept responsibility for the contents of this announcement.
For further information, please contact:
|
ANANDA DEVELOPMENTS PLC |
+44 (0)7463 686 497 |
|
|
ir@anandadevelopments.com |
|
Chief Executive Officer |
|
|
Melissa Sturgess |
|
|
|
|
|
Finance Director |
|
|
Jeremy Sturgess-Smith |
|
|
|
|
|
SP ANGEL CORPORATE FINANCE LLP |
+44 (0)20 3470 0470 |
|
|
|
|
Corporate Finance |
|
|
Richard Morrison |
|
|
Caroline Rowe |
|
|
|
|
|
Corporate Broking |
|
|
Abigail Wayne |
|
|
Rob Rees
|
|
|
Yellow Jersey PR (media enquiries) Sarah MacLeod Charles Goodwin Zara McKinlay |
+44 (0)20 3004 9512 ananda@yellowjerseypr.com |
https://investors.anandadevelopments.com/link/lya71r
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
